California Assembly Bill AB2571

California 2025-2026 Regular Session

• Introduced: 2/20/26
• Refer: 3/9/26
• Report Pass: 3/25/26
• Refer: 3/25/26
• Report Pass: 4/8/26
• Engrossed: 4/16/26
• Refer: 4/16/26
• Refer: 5/6/26
• Report Pass: 5/20/26
• Refer: 5/20/26
• Report Pass: 6/4/26
• Refer: 6/8/26

Caption

An act to amend Section 1368.5 of the Health and Safety Code, to amend Section 10125.1 of the Insurance Code, and to amend Sections 14132.968 and 14132.969 of the Welfare and Institutions Code, relating to healing arts.

Impact

The impact of AB 2571 on state laws is considerable, as it aligns pharmacist reimbursement structures more closely with those of physicians, which could lead to an increase in the number of pharmacists providing services under Medi-Cal. By ensuring that advanced practice pharmacists are compensated fairly, the bill also promotes better access to healthcare services in the community. This may result in improved healthcare outcomes, particularly in medication management and therapy, as pharmacists are essential in consulting on drug therapies and addressing medication adherence issues.

Summary

Assembly Bill 2571, introduced by Assembly Member Flora, seeks to amend the California law to enhance the reimbursement rates for pharmacist services under the Medi-Cal program and other related healthcare plans. The bill stipulates that advanced practice pharmacists should receive reimbursement rates equivalent to those set for physician services, thereby promoting equitable compensation for similar roles within the healthcare system. This change is significant as it aims to recognize the evolving roles of pharmacists in providing essential healthcare services, particularly in underserved areas.

Contention

While the intent of AB 2571 is to enhance healthcare delivery through better reimbursement practices, it may face contention regarding the implications for health insurers and the financial burden on the Medi-Cal program. Some stakeholders may argue that increasing reimbursement rates could lead to higher costs for state-funded programs. Moreover, the requirement for compliance and the potential legal ramifications for health plans could raise concerns among insurers about their operational flexibility. Balancing fair compensation for pharmacists with sustainable healthcare funding will likely be a critical debate as the bill progresses through the legislative process.